Phathom Pharmaceuticals, Inc. (PHAT) Balance Sheet
As of 2026-06-30 (10-Q), Phathom Pharmaceuticals, Inc. (PHAT) reported total assets of $327.1M, total liabilities of $671.3M and shareholders' equity of -$344.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $182.5M. Long-term debt: $164.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PHATPhathom Pharmaceuticals, Inc.Follow PHAT — free
—
Price chart with a free account
- Market cap
- 464.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 243.8 | 287.5 | 183.3 | 155.4 | 381.4 | 297.3 | 130.0 | 182.5 | |
| Receivables | — | — | — | 0.0 | 1.6 | 38.8 | 78.1 | 97.4 | |
| Inventory | — | — | — | 0.0 | 1.2 | 3.2 | 5.5 | 7.7 | |
| Current assets | 255.6 | 291.4 | 186.5 | 160.5 | 397.4 | 360.1 | 229.0 | 295.9 | |
| Total assets | 257.2 | 295.1 | 189.4 | 164.8 | 413.8 | 378.3 | 259.1 | 327.1 | |
| Current liabilities | 3.7 | 55.5 | 18.9 | 26.2 | 38.8 | 85.7 | 132.0 | 153.8 | |
| Long-term debt | 22.8 | 39.6 | 89.7 | 95.3 | 137.8 | 201.4 | 209.1 | 164.6 | |
| Short-term debt | — | 7.4 | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total liabilities | 29.2 | 100.8 | 117.3 | 239.6 | 486.6 | 631.9 | 697.3 | 671.3 | |
| Shareholders' equity | 228.0 | 194.3 | 72.2 | -74.8 | -72.8 | -253.6 | -438.2 | -344.3 |
USD millions · SEC XBRL
Phathom Pharmaceuticals, Inc. — questions
- How much cash does Phathom Pharmaceuticals, Inc. have?
- $182.5M in cash and cash equivalents as of 2026-06-30.
- How much debt does Phathom Pharmaceuticals, Inc. have?
- $164.6M of long-term debt and $0 due within a year as of 2026-06-30.
- What are Phathom Pharmaceuticals, Inc.'s total assets?
- $327.1M as of 2026-06-30.
- What is Phathom Pharmaceuticals, Inc.'s shareholders' equity?
- -$344.3M as of 2026-06-30.
Every figure on this page comes from Phathom Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.